Martan A, Mašata J, Svabík K, El-Haddad R, Hubka P
Ceska Gynekol. 2013 Dec;78(6):554-9.
The objective of this study was to evaluate short term and long term efficacy of a transurethral injection (TUI) using bulking agent Bulkamid® for female stress (SUI) and mixed urinary incontinence by women with ISD or where anti-incontinence surgery has failed.
Retrospective clinical study.
Gynecological and Obstetric Dpt. 1st Medical Faculty UK and VFN, Prague.
A retrospective study was performed on 52 women with urinary incontinence (stress, 43; mixed 9). One patient died during study. Forty patients had previously undergone anti-incontinence surgery. The efficacy of TUI was evaluated 3 months (± 1 week) and an average of 22 months after surgery. Subjective assessment of the leakage of urine was based on the International Consultation on Incontinence Questionnaire - Short form (ICIQ-UI SF) filled in before, three and - on average - 22 months after the surgery (minimum time after surgery was 6 months). Improvement in urinary incontinence was defined as a drop in the score of more than 50%. Objective assessment of leakage of urine was assessed by cough test. The cure effect was evaluated by VAS (Visual Analogue Scale) score and by using the five-point Likert score. Ethical committee approval was obtained, and all subjects gave written informed consent to participate in the study.
Mean age of patients was 70 years, mean body mass index (BMI) 28.65, and mean parity was 1.76. The cough test showed that 19/51 (37.3%) of patients had negative results for this test 3 months and 10/51 (19.6%) 22 months after the operation. The ICIQ-UI SF questionnaire showed that 16/51 (31.4%) of our patients were completely dry 3 months after the operation and 8/51 (15.7 %) 22 months after the operation. 41/51 (80.4%) of patients were dry or improved 3 months after the operation and 23/51 (45.13%) 22 months after the operation. The mean cure effect evaluated by VAS score 3 months after the operation was 72 and 22 months after the operation it was 51.3. The Likert score was 4 or 5 (cured or improved) three and 22 months after operation by 78.4% / 54.9% patients.
The cure effect of Bulkamid® operation decreases in correlation with the time that elapses after the operation, although this procedure is minimally invasive and is an option in cases where anti-incontinence surgery has failed.
本研究的目的是评估使用填充剂Bulkamid®经尿道注射(TUI)治疗女性压力性尿失禁(SUI)及混合性尿失禁的短期和长期疗效,这些女性患有内在括约肌缺陷(ISD)或抗尿失禁手术失败。
回顾性临床研究。
布拉格英国第一医学院和VFN妇产科。
对52例尿失禁女性(压力性尿失禁43例,混合性尿失禁9例)进行回顾性研究。1例患者在研究期间死亡。40例患者此前接受过抗尿失禁手术。在术后3个月(±1周)及平均22个月评估TUI的疗效。基于术前、术后3个月及平均22个月(术后最短时间为6个月)填写的《国际尿失禁咨询问卷 - 简表》(ICIQ-UI SF)对尿液渗漏进行主观评估。尿失禁的改善定义为得分下降超过50%。通过咳嗽试验对尿液渗漏进行客观评估。通过视觉模拟量表(VAS)评分和五点李克特评分评估治愈效果。获得伦理委员会批准,所有受试者均签署书面知情同意书参与本研究。
患者平均年龄70岁,平均体重指数(BMI)28.65,平均产次1.76。咳嗽试验显示,术后3个月19/51(37.3%)的患者该试验结果为阴性,术后22个月10/51(19.6%)的患者该试验结果为阴性。ICIQ-UI SF问卷显示,术后3个月16/51(31.4%)的患者完全无尿失禁,术后22个月8/51(15.7%)的患者完全无尿失禁。术后3个月41/51(80.4%)的患者无尿失禁或病情改善,术后22个月23/51(45.13%)的患者无尿失禁或病情改善。术后3个月通过VAS评分评估的平均治愈效果为72,术后22个月为51.3。术后3个月和22个月,78.4%/54.9%的患者李克特评分为4或5(治愈或改善)。
尽管Bulkamid®手术微创且是抗尿失禁手术失败情况下的一种选择,但其治愈效果随术后时间推移而降低。